One of the only markets that still offer massive upside is that of healthcare. One company recently received FDA approval to test two breakthrough drugs.

This company has already soared 50% in a week’s time. But the fundamentals say this company is primed for a long-term climb up the charts.

In 2002, Alkermes thought it had a winner on its hands… The small biotech and its Big Pharma partner, Johnson & Johnson, had developed the drug Risperdal Consta to combat schizophrenia. It was a great deal for a while… The market assumed the drug would be approved by the FDA the first time around.